Cancer specialists and researchers are increasingly optimistic as the National Cancer Institute (NCI) Cancer Moonshot Initiative continues to drive momentum for research in cancer prevention, detection, treatment, basic science and translational medicine. With $1.8 billion over 7 years from the 21st Century Cures Act, the Cancer Moonshot not only provides crucial supplemental funding, it continues to cultivate cooperation and resolution across agencies, hospitals and research institutions.
As an example of this momentum, The Lancet Oncology Commission recently published a report outlining future cancer research priorities in the U.S., intending the document to serve as a granular perspective on the research roadmap outlined by Moonshot’s Blue Ribbon Panel. The commission details effective implementation strategies, the promise of immunotherapy and precision-based therapies, and ways of understanding and eliminating health disparities, all part of a larger call to action to achieve 10 years of research progress in five.
At The Lancet Senate Briefing on November 1, professor of oncology and deputy director of the Johns Hopkins Sidney Kimmel Cancer Center Elizabeth Jaffee, M.D., emphasized the importance of core investments for the National Institutes of Health and NCI that have supported breakthroughs in cancer research, many of which are leading the technological revolution that is driving next generation cancer treatment strategies.
To read more on The Lancet Oncology Commission, click here.